These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20109144)

  • 1. Conditioned avoidance response in the development of new antipsychotics.
    Wadenberg ML
    Curr Pharm Des; 2010 Jan; 16(3):358-70. PubMed ID: 20109144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
    Olsen CK; Brennum LT; Kreilgaard M
    Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
    Wadenberg ML; Fjällström AK; Federley M; Persson P; Stenqvist P
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):644-54. PubMed ID: 20701827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
    Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
    Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
    Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of antipsychotic-like effects by combined treatment with the alpha1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats.
    Wadenberg ML; Hertel P; Fernholm R; Hygge Blakeman K; Ahlenius S; Svensson TH
    J Neural Transm (Vienna); 2000; 107(10):1229-38. PubMed ID: 11129112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity.
    McQuade RD; Duffy RA; Coffin VL; Barnett A
    Eur J Pharmacol; 1992 Apr; 215(1):29-34. PubMed ID: 1355442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
    Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
    Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mGlu(2) receptor-mediated modulation of conditioned avoidance behavior in rats.
    Megens AA; Hendrickx HM; Hens KA; Talloen WJ; Lavreysen H
    Eur J Pharmacol; 2014 Mar; 727():130-9. PubMed ID: 24486391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats.
    Wadenberg MG; Browning JL; Young KA; Hicks PB
    Pharmacol Biochem Behav; 2001 Mar; 68(3):363-70. PubMed ID: 11325387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.
    Gacsályi I; Nagy K; Pallagi K; Lévay G; Hársing LG; Móricz K; Kertész S; Varga P; Haller J; Gigler G; Szénási G; Barkóczy J; Bíró J; Spedding M; Antoni FA
    Neuropharmacology; 2013 Jan; 64():254-63. PubMed ID: 22824189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
    Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does antagonism at 5-HT2A receptors potentiate D₂ blockade-induced disruption of conditioned avoidance response?
    Gao J; Huang Y; Li M
    Exp Clin Psychopharmacol; 2019 Apr; 27(2):103-108. PubMed ID: 30556732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone.
    Ohno Y; Ishida-Tokuda K; Ishibashi T; Sakamoto H; Tagashira R; Horisawa T; Yabuuti K; Matsumoto K; Kawabe A; Nakamura M
    Pol J Pharmacol; 1997 Aug; 49(4):213-9. PubMed ID: 9437764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?
    Wadenberg ML; Hicks PB
    Neurosci Biobehav Rev; 1999; 23(6):851-62. PubMed ID: 10541060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral pharmacology of olanzapine: a novel antipsychotic drug.
    Moore NA; Leander JD; Benvenga MJ; Gleason SD; Shannon H
    J Clin Psychiatry; 1997; 58 Suppl 10():37-44. PubMed ID: 9265915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
    Langlois X; Megens A; Lavreysen H; Atack J; Cik M; te Riele P; Peeters L; Wouters R; Vermeire J; Hendrickx H; Macdonald G; De Bruyn M
    J Pharmacol Exp Ther; 2012 Jul; 342(1):91-105. PubMed ID: 22490380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.
    Sparkman NL; Li M
    Behav Pharmacol; 2012 Oct; 23(7):658-68. PubMed ID: 22903071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.